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Abstract
Background: A single variant in NAA10 (c.471+2T>A), the gene encoding N-acetyltransferase 10, 
has been associated with Lenz microphthalmia syndrome. In this study, we aimed to identify 
causative variants in families with syndromic X-linked microphthalmia. 
Methods: Three families, including 15 affected individuals with syndromic X-linked 
microphthalmia, underwent analyses including linkage analysis, exome sequencing and 
targeted gene sequencing. The consequences of two identified variants in NAA10 were 
evaluated using quantitative PCR and RNAseq. 
Results: Genetic linkage analysis in family 1 supported a candidate region on Xq27-28, which 
included NAA10. Exome sequencing identified a hemizygous NAA10 polyadenylation signal 
(PAS) variant, chrX:153,195,397T>C, c.*43A>G, which segregated with the disease. Targeted 
sequencing of affected males from families 2 and 3 identified distinct NAA10 PAS variants, 
chrX:g.153,195,401T>C, c.*39A>G and chrX:g.153,195,400T>C, c.*40A>G. All three variants 
were absent from gnomAD. Quantitative PCR and RNAseq showed reduced NAA10 mRNA levels 
and abnormal 3’ UTRs in affected individuals. Targetted sequencing of NAA10 in 376 additional 
affected individuals failed to identify variants in the PAS.
Conclusion: These data show that PAS variants are the most common variant type in NAA10-
associated syndromic microphthalmia, suggesting reduced RNA is the molecular mechanism by 
which these alterations cause microphthalmia/anophthalmia. We reviewed recognized variants 
in PAS associated with Mendelian disorders and identified only 23 others, indicating that NAA10 
harbors more than 10% of all known PAS variants. We hypothesize that PAS in other genes 
harbor unrecognized pathogenic variants associated with Mendelian disorders. The systematic 
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interrogation of PAS could improve genetic testing yields.
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Introduction
Congenital anophthalmia and microphthalmia result from failure of early eye development. 
One-third of affected individuals are syndromic[1],[2] and it is genetically heterogeneous.[3] X-
linked syndromic anophthalmia and microphthalmia have been shown to result from 
pathogenic variants in four genes: BCOR[4] (MIM:300485, MCOPS2), HCCS[5] (MIM:300056, 
MCOPS7), HMGB3[6] (MIM:300193, MCOPS13), and NAA10[7] (MIM:309800, MCOPS1). A fifth 
locus, MCOPS4 (MIM:301590, also designated as ANOP1), with linkage to Xq27-q28, was 
specified without identification of an associated gene. HMGB3 and NAA10 reside on Xq27-
Xq28. A single HGMB3 variant has been reported in one family to cause syndromic 
colobomatous microphthalmia.[6] Forrester et al. described a family segregating what they 
termed Lenz microphthalmia syndrome (LMS) and linkage to Xq27-q28.[8] Affected individuals 
had severe microphthalmia, renal anomalies, high-arched palate, cutaneous syndactyly of the 
hands, and severe intellectual disability (ID). A c.471+2T>A splice variant in NAA10 was 
identified as causative, the only study to date associating NAA10 variants with syndromic 
microphthalmia.[7]
The MCOPS4 locus was originally defined based on a family reported by Graham et al.[9] 
Their manifestations included microphthalmia/anophthalmia and ID in multiple affected males. 
Here, we re-analyze this family using genetic linkage analysis and exome sequencing, verified 
our findings in two additional families, and functionally characterized the variants. 
Materials and Methods
This study was approved by Institutional Review Boards at the National Institutes of Health, the 
UK Multicentre Research Ethics Committee (MREC), the University of Michigan, the University 
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of California, Davis, and the Huntingdon Ethics Committee, UK. All DNA analyses were 
performed using standard techniques. 
Linkage and haplotype analyses
Resampling and repeat genetic linkage analyses were performed in family 1 (Figure 1A) using 30 
microsatellite markers on the X chromosome. Initial analyses of 22 markers spanning the X 
chromosome were followed by fine mapping with an additional eight markers from the region 
near Xqtel. LOD scores were computed using FASTLINK using equal marker allele 
frequencies.[10], [11], [12] For multi-marker analyses, inter-marker recombination fractions 
were derived from the Rutgers map.[13] The disease locus was modeled as X-linked recessive. 
Analyses were performed under two additional possible scenarios, first that the individual I-2 
was gonadal mosaic and second that penetrance was less than 100%. Haplotype analysis was 
performed assuming a model of X-linked recessive inheritance.
Sequence analyses
The coding region and consensus splice sites of two candidate genes, NAA10 and HMGB3, were 
analyzed in family 1 using Sanger sequencing. Exome sequencing was performed on individual 
IV-3 and his parents at the NIH Intramural Sequencing Center (NISC), as described.[14] 
Identified variants in the linkage region were filtered for quality, absence in ExAC males and 
absence in 473 males from an in-house dataset.[15],[16] Sanger sequence analyses were 
performed in family 1 to confirm segregation. Targeted Sanger sequencing of NAA10 was 
performed in the proband of family 2 (Figure 1B). Independently, sequence analysis of a panel 
of 41 genes causally associated with severe eye malformations was carried out on the proband 
in family 3 (Figure 1C) using a custom-designed Agilent SureSelect panel (Agilent Technologies, 
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Inc., Santa Clara, CA) and paired-end DNA sequencing using an Illumina MiSeq platform 
(Illumina, San Diego, CA), as per the manufacturer’s instructions. Targeted sequencing of the 
NAA10 polyadenylation signal (PAS) was performed in 250 unrelated 
microphthalmia/anophthalmia/coloboma patients selected without sex bias from the MRC 
Human Genetics Unit Eye Malformation cohort. A further 126 males with developmental eye 
disorders underwent targeted sequencing of the NAA10 PAS. Forty-four of these individuals 
with bilateral developmental eye disorders were analysed for variants in the coding region and 
consensus splice sites of NAA10.
X-inactivation analyses
X-inactivation studies were performed on genomic DNA from 11 carrier females (family 1
individuals I-2, II-2, II-6, II-17, III-15; family 2 individuals III-2, III-3, IV-1, IV-5, V-8; family 3 
individual I-2) using the human androgen receptor (HUMARA) assay as described in Allen et 
al[17] with minor modifications. Briefly, genomic DNA was digested with Rsa1 either alone or 
with the addition of HpaII (New England Biolabs, Ipswich, MA). Digested DNA was PCR amplified 
using primers HUMAR_F: /56-FAM/TCCAGAATCTGTTCCAGAGCGTGC and Humara_R: 
GCTGTGAAGGTTGCTGTTCCTCAT (Integrated DNA Technologies, Inc. Coralville, Iowa). Products 
were run on an 3130xl genetic analyzer (ThermoFisher Scientific, Waltham, MA) and analyzed 
using GeneMapper v4.0 (ThermoFisher Scientific, Waltham, MA).
RNA Analyses
Total RNA was isolated from whole blood from affected and carrier individuals in family 1 and 
from unrelated male and female controls using PAXgene Blood RNA tubes (BD Biosciences, San 
Jose, CA). Total RNA was isolated from lymphoblasts from one affected and one unaffected 
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individual in family 2 using the RNeasy Mini kit (Qiagen, Germantown, MD). RNA samples were 
not available from family 3. RNA-Seq libraries were constructed from 0.5-1 µg total RNA after 
rRNA depletion using Ribo-Zero Globin (Illumina, San Diego, CA). The Illumina TruSeq Stranded 
Total RNA Kit was used according to manufacturer’s instructions. The cDNA inserts were ~200 
bp after chemical shearing. PCR amplification was performed using 10 cycles. Unique barcode 
adapters were applied to each library. Libraries were pooled in equimolar ratio for sequencing. 
The pooled libraries were sequenced on multiple lanes of a HiSeq 2500 (Illumina, San Diego, CA) 
using version 4 chemistry to achieve a minimum of 69 million 125 base read pairs. The data 
were processed using RTA version 1.18.64 and CASAVA 1.8.2. RNA-Seq reads were aligned with 
the STAR aligner,[18] using the hg19 genome assembly and the Ensembl transcript database 
(release 74). The STAR BAM output file was converted to WIG format using the bam2wig.py 
script from the RSeqC suite,[19] and these WIG files were further converted to bigwig format 
using the wigToBigWig tool from the UCSC Genome Browser's binary utilities directory.
For quantitative PCR (qPCR), 400 ng total RNA was converted to cDNA using the High Capacity 
RNA-to-cDNA kit (Applied Biosystems, Beverly, MA). TaqMan assays were performed using 10 
ng cDNA, gene specific TaqMan probes (NAA10: HS01125831_g1 and HA00185854_m1; beta-
Actin: Hs99999903_m1 (Thermo Fisher Scientific, Waltham, MA)) and TaqMan Gene Expression 
Master Mix (Applied Biosytems, Beverly, MA) on the OneStepPlus Real-Time PCR System 
(Thermo Fisher Scientific, Waltham, MA). Samples were run in triplicate and relative expression 
levels in affected and carrier individuals as compared to control individuals were calculated 
using the delta-delta Ct method.
Results
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Clinical evaluations
Family 1 
Family 1 (Figure 1A) was originally described by Graham et al. in support of a fifth 
microphthalmia/anophthalmia locus MCOPS4. The family was reported to include seven 
affected males with microphthalmia/anophthalmia and ID.[9] One male, II-18, was reported to 
have normal eyes with cleft soft palate and a single ear tag and was considered unaffected with 
respect to syndromic anophthalmia/microphthalmia. An additional affected male, IV-3, with a 
milder phenotype as compared to his affected uncles, was born after publication of the Graham 
et al paper.[9] Briefly, this male infant was born following a pregnancy in which scans were 
assessed to be normal. However, at birth he was noted to have a large open neural tube defect 
(NTD), right sided anophthalmia, and bilateral 2-3 cutaneous syndactyly of his toes. When his 
teeth erupted they were irregular. He was sociable and did not show signs of the severe 
developmental delay or behavioral problems, most notably self-mutilation, seen in other 
affected males in the family.
Family 2
Family 2 (Figure 1B) was originally described by Slavotinek et al.[20] as a four-generation family 
with X-linked anophthalmia consistent with linkage to Xq27. The intelligence of two living males 
in family 2 was apparently normal. Carrier females III-2 and IV-1 had unremarkable eye 
examinations, individual IV-1 was diagnosed with dyslexia but her intelligence was apparently 
normal.
Family 3
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The male proband (individual II-2, Figure 1C) was the second child of a non-consanguineous 
couple, referred for diagnostic screening of genes associated with severe eye malformations. 
Family history was remarkable for a maternal uncle with anencephaly. The proband presented 
with spina bifida at 20 weeks gestation. He was a term delivery with birth weight 3.2 Kg. At 
birth, he was noted to have widely spaced eyes, unilateral phthisis bulbi, downturned corners 
of the mouth, small penis, and small feet with upturned nails. At eight months his length, 
weight, and head circumference were recorded at 9th centile. He had a repaired 
myelomeningocele, hydrocephalus with a ventriculoperitoneal shunt, and left grade 2 vesico-
ureteric reflux with a normal renal ultrasound. MRI studies showed ventriculomegaly with a 
Chiari type 2 malformation. Developmental milestones were reported to be normal at 8 
months. Array CGH was reported as normal. 
Molecular Data
Family 1
LOD score analyses reported in the original paper showed a peak logarithm of odds (LOD) score 
of 1.9, between the disease and markers on Xq27-q28, below the 2.0 threshold recommended 
to declare X-chromosome linkage.[21] The evidence of linkage was weak unless one assumed 
non-penetrance, pleiotropy, variable expressivity, or gonadal mosaicism as the mutant 
haplotype was shared by II-18 and his affected relatives.
Repeat multi-marker analysis using four informative markers DXS8091, DXS1193, DXS8086, and 
DXS1073 achieved a peak LOD score of 1.43 with the disease locus placed on top of DXS1073 
and assuming full penetrance. The peak multi-marker score was 2.19 with 75% penetrance, 
2.46 with 50% penetrance, and 3.31 assuming gonadal mosaicism. Haplotype analysis was 
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performed assuming a model of X-linked recessive inheritance and showed a recombination 
event in affected individual III-2 between markers DXS8043 and DXS8086 restricting the 
possible linkage region telomeric to position ChrX(GRCh37):g.144,028,513.
Both HMGB3 and NAA10 lie within this linkage region. The coding regions and 
consensus splice sites of HMGB3 and NAA10 were interrogated without identification of a 
pathogenic variant. Trio exome sequencing was performed on individual IV-3 and his parents 
and variants in the linked region were filtered for absence in male controls. A single variant was 
identified in the 3’UTR of NAA10, chrX:153,195,397T>C, c.*43A>G (reference cDNA 
NM_003491.3), altering the consensus PAS from AATAAA to AATAGA. The NAA10 variant was 
verified by Sanger sequencing and shown to be present in all affected individuals available for 
analysis, the matriarch (I-2), as well as in individual II-18, the male previously thought to be 
unaffected. Querying the gnomAD database for variants in the consensus PAS for NAA10 did 
not identify any variants in over 170,000 alleles.
Family 2
A reexamination of the linkage data showed that family 1 and family 2 had overlapping regions 
near Xqtel consistent with linkage. Based on the findings in family 1, targeted Sanger 
sequencing of NAA10 was performed in the proband of family 2. A second distinct variant in the 
the 3’UTR of NAA10, chrX:g.153,195,401T>C, c.*39A>G, was identified, which altered the 
consensus PAS from AATAAA to GATAAA. The variant was verified by Sanger sequencing in 
carrier females and was not present in two unaffected males.
Family 3
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Targeted sequencing of 41 genes causally associated with severe eye malformations in the 
proband from family 3 identified a third variant in NAA10, chrX:g.153,195,400T>C , c.*40A>G, 
that altered the consensus PAS from AATAAA to AGTAAA. The NAA10 variant in family 3 was 
confirmed by Sanger sequencing. DNA from the uncle with anencephaly was not available for 
testing. 
NAA10 Sequence Analysis in Microphthalmia/Anophthalmia/Coloboma Cohorts
Targeted sequencing of the NAA10 PAS in 250 unrelated 
microphthalmia/anophthalmia/coloboma patients selected without sex bias from the MRC 
Human Genetics Unit Eye Malformation cohort did not identify additional variants. No variants 
affecting the NAA10 PAS were identified in a further 126 males with developmental eye 
disorders. In addition, no pathogenic variants in the coding region and consensus splice sites of 
NAA10 were identified in 44 of these individuals who presented with bilateral developmental 
eye disorders.
X-Inactivation
Four of 11 carrier females showed greater than 90% skewing of X-inactivation, individual II-2 
from family 1 and individuals III-2, IV-1 and IV-5 from family 2. However, females did not show 
consistent skewing of X-inactivation.
RNA analyses
The consequences of the PAS variants for NAA10 mRNA expression level and structure were 
investigated using qPCR and RNAseq in families 1 and 2. qPCR showed carrier females from 
family 1 to have similar levels of NAA10 RNA as compared to control individuals. In contrast, 
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affected individuals from families 1 and 2 demonstrated a decrease in the quantity of NAA10 
RNA of approximately 50% when compared to controls (Figure 2).
Transcript structure was investigated by mapping RNAseq reads to the UCSC Genome 
Browser. RNAseq data from unaffected (family 2, individual V-9) and control individuals 
indicated the normal 3’UTR of NAA10 ended at the approximate position of the predicted 
polyadenylation site (Figure 3G-I). In contrast, for affected individuals with the PAS variants 
(family 1, individuals III-2, III-5, IV-3 and family 2, individual IV-6), the read depth did not 
decrease as expected at the polyadenylation site in the 3’UTR, but instead declined 
approximately 600 bp further 3’ at a second polyadenylation site predicted by bioinformatic 
analysis of genomic sequence (Figure 3A-C, F).[22] A similar result was observed in carrier 
females (family 1, individuals II-2 and III-15) (Figure 3D-E). 
Discussion
Six protein complexes, NatA through NatF, carry out Nα acetylation of proteins in the 
cell.[23],[24] NAA10 is the primary subunit of the NatA complex and an auxiliary subunit of the 
NatE complex.[24],[25] The acetylation targets of the six complexes are believed to be mostly 
distinct and dependent on the amino acids that follow the methionine in position 1.[24] 
Additionally, data from a knock-out mouse model suggests that NAA10 plays a role in the 
regulation of methylation through direct DNA binding.[26] Prior to the present publication, the 
mutational spectrum in NAA10 comprised nine missense alterations and the single splice site 
variant identified previously in a single family with what those authors called LMS. The first 
reported variant in NAA10, c.109T>C; p.(Ser37Pro), was identified in two families segregating a 
sex-linked recessive male lethal syndrome with an aged appearance and cardiac 
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arrhythmias.[27] Eight additional missense variants have since been reported in heterozygous 
females or hemizygous males with developmental delay and/or ID with or without cardiac 
involvement and without anophthalmia.[28],[29],[30],[31],[32] The majority of these variants 
were identified as de novo alterations.[28],[30],[31],[32] Functional studies of the missense 
alterations have demonstrated a variable effect on the ability of NAA10 to acetylate substrates 
and the clinical phenotype may correlate with the level of acetylation dysfunction and affected 
substrates. Alternatively, clinically relevant predicted missense variants in NAA10 have been 
shown to disrupt DNA binding[26] and it is likely that different missense alterations will variably 
contribute to this phenomenon. 
The polyA_DB database contains human mRNA polyadenylation sites based on EST/cDNA 
evidence[33] and predicts four sites in the 3’ region of NAA10. Based on the NAA10 Poly(A) 
sequence data in the UCSC Genome Browser, the PAS at c.*39 – c.*44 is the most commonly 
used signal with polyadenylation occurring between 12-19 nucleotides 3’ of that hexamer. 
Three distinct nucleotides within this six-nucleotide signal are mutated in the families described 
here. Previous in vitro studies have demonstrated that these changes in the PAS hexamer 
disrupt both cleavage and polyadenylation (Figure 4).[34] Furthermore, these variants are 
analogous to variants associated with abnormal phenotypes in other genes. The NAA10 3’UTR 
variant identified in family 1, c.*43A>G, alters the AATAAA consensus to AATAGA, similar to the 
c.*112A>G (reference cDNA NM_000518.4) pathogenic variant in the beta globin (HBB) gene 
(HGMD CR900266) (See Table 1).[35] The 3’UTR variant of NAA10 identified in family 2, 
c.*39A>G, alters the AATAAA consensus to GATAAA, similar to another reported pathogenic 
variant in the HBB gene, (c.*108A>G, HGMD CR127145).[36] The NAA10 3’UTR variant 
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identified in family 3 , c.*40A>G, alters the AATAAA consensus to AGTAAA, similar to the variant 
in the ARSA gene (HGMD CR890137) reported by Gieselmann et al[37] and a variant in the 
SLC6A4 gene (HGMD CR102248) reported by Gyawali et al[38] although it is important to note 
that the wild-type PAS consensus sequence in both ARSA and SLC6A4 genes is AATAAC, (See 
Table 1). That the NAA10 variant disrupts a consensus PAS rather than a non-canonical PAS 
could be consistent with the observation that the NAA10 variants are associated with a 
Mendelian disorder whereas the ARSA and SLC6A4 variants are associated with lower 
penetrance traits. 
All three families presented here manifested microphthalmia/anophthalmia with 
variable additional features. In family 1, individuals had variable expressivity ranging from 
syndromic microphthalmia/anophthalmia with severe ID to isolated cleft palate and an ear tag. 
A single individual, IV-3, had an open NTD. Affected individuals in family 2 had anophthalmia 
and additional findings including minor skeletal anomalies and attention deficit disorder, but 
notably all affected males were reported to have normal intelligence. The proband in family 3 
had syndromic microphthalmia/anophthalmia with complex features including spina bifida. By 
report, a maternal uncle (deceased) to the proband had anencephaly, however, his genotype 
was unknown. Although the numbers are small, two out of 15 individuals in this study had NTDs 
(three if the uncle in family 2 is included). Additional families will need to be studied to 
determine if NTDs are a feature of NAA10 PAS variants. The mouse NAA10 knock-out model 
had variable expressivity ranging from embryonic lethality to normal body size and Lee et al. 
suggested this variable expressivity may result from the role of NAA10 in global 
methylation.[26] The role of NAA10 in global methylation may contribute to the observed 
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variable expressivity in these families as well. Specifically, the observed phenotype may result 
from the regions of the genome experiencing defective methylation in any one individual. As 
methylation is important in the etiology of NTDs it is interesting to speculate that the role of 
NAA10 in global methylation may account for the NTDs seen in these families. Future studies 
will be needed to determine if methylation or other factors play a role in the variable 
expressivity seen with these variants.
 Cleavage and polyadenylation signals reside in the 3’ UTRs of mRNAs and include a 
number of key cis elements including the AAUAAA PAS which typically resides 10-30 
nucleotides upstream of the cleavage site (reviewed in [39],[40]). Ninety percent of identified 
PAS conform to the hexanucleotide sequence AAUAAA and most of the remaining 10% differ by 
only a single substitution.[39] The AAUAAA hexamer is critical both for cleavage and poly(A) 
addition,[41] and the effects of point mutations in this hexamer have been determined.[34] 
Disease-associated variants in PAS are rare and consequently we were surprised to identify 
three such variants in this rare disorder. To identify all known consensus PAS variants, we 
performed a directed search of the Human Gene Mutation Database (HGMD).[42] We 
identified 31 reported PAS variants in 19 genes (Table 1), 23 associated with Mendelian 
disorders and eight associated with a functional polymorphism or susceptibility. Overall, PAS 
variants account for 23 out of the ~195,000 DM variants in HGMD, or 0.012% of the total. As 
well as being individually uncommon, such variants have a highly non-random distribution 
across genes. Of the 23 variants associated with Mendelian disorders, nine are in HBB, four are 
in HBA2, and two are in FOXP3, the remainder being singletons. Some of this distribution can be 
explained by the depth and detail to which the various genes have been studied, HBB being one 
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of the best studied of all human genes. To allow for this, the proportion of polyadenylation 
variants to all known pathogenic variants in a given gene can be tabulated. When expressed in 
this way, a very different pattern emerges. NAA10 has the highest proportion of PAS variants, 
at 25%. The next highest cluster of genes includes IGF1, NAT1, BMP1, and SLC6A4, each of 
which has a single PAS variant, but a relatively small overall number of variants, yielding a high 
proportion. HBB and HBA2 lie in the middle of the range at about 1% of variants, reflecting the 
large number of variants in these well-studied genes. Most of the clinical phenotypes 
associated with PAS variants are typical of those seen for loss of function variants in the same 
gene although they may be found with milder forms of the phenotypes – for example, in 
HBB,[36],[ 43] the phenotypes of PAS variants are described as either typical or mild 
thalassemia. The contribution to milder phenotypes has two implications, first in disorders 
where loss of gene function would be lethal, PAS variants may allow sufficient function for 
viability. Second, for disorders where the phenotype is due to complete loss of function, PAS 
variants may be missed if they lead to a milder condition.[36] We conclude from these data 
that the phenotypic consequence of pathogenic PAS variants is likely due to loss or partial loss 
of function, consistent with the experimental observations of these variants in other genes and 
the qPCR data we show here. Specifically, for NAA10, this suggests that partial loss of protein 
function due to reduced mRNA levels leads to a distinct phenotype, as compared to missense 
variants where the functional deficiency may only affect specific acetylation or DNA binding 
functions. The previously reported NAA10 splice site variant[7] also showed reduced 
mRNA/protein supporting reduced function as causal for the microphthalmia phenotype. 
Alternatively, sequences within the elongated 3’ end, or within the retained intron 7 for the 
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splice variant, may have a novel functional effect. Possible novel effects include: altered RNA or 
protein localization[44], altered 3’UTR-directed protein-protein interactions[45], or acquisition 
of novel regulatory functions. However, since the retained sequences are distinct between the 
splice site variant and the PAS variants, a novel property of the mRNA is unlikely to be the 
mechanism accounting for the overlapping feature of microphthalmia. Additionally, the 
absence of a phenotype in carrier females without skewed X-inactivation suggests that any 
effect would need to fit a recessive model of inheritance. The general dearth of recognized PAS 
pathogenic variants may be in part due to the inherent difficulty in identifying PAS. In addition, 
many such variants may not be included in next generation sequence data due to the 
limitations of exome sequencing kits and the predominant use of exome over genome 
sequencing.
The assessment of pathogenicity for non-coding variants in Mendelian disorders is 
challenging. The ACMG/AMP [46] framework includes few criteria that are relevant to 3’ UTR 
variants, reflecting a focus on high penetrance coding variants. For the variants we identified 
here, we invoked criteria PS3 (well-established in vitro or in vivo functional studies), PM1 
(located in a mutational hot spot and/or critical and well-established functional domain), PM2 
(absent from controls), and PP1 (co-segregation with disease in multiple affected family 
members). As qPCR is not “a well-established functional assay” because qPCR for NAA10 is not 
established in the diagnostic realm, the PS3 criteria can be downgraded to a moderate level of 
evidence (PS3_Mod). Additionally, our segregation data are arguably less than robust 
considering that we have invoked variable expressivity to explain the occurrence of the variant 
in II-18 in family 1 and thus PP1 might arguably be dropped. That would leave PS3_Mod, PM1, 
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and PM2, which combine to yield a likely pathogenic assessment. Based on these pieces of 
evidence, we conclude that these three PAS variants are likely pathogenic. 
These data have important implications for the overall process of identifying pathogenic 
variation. We hypothesize that PAS variants are candidate pathogenic variants for many 
Mendelian disorders and may be a component of the mutational spectrum of patients who are 
currently ‘mutation-negative’. A full assessment of this hypothesis will first require the 
continued development of genome (as opposed to exome) population sequence reference 
databases, allowing a greater understanding of the evolutionary constraints operating at 3’ UTR 
loci. Second, robust methods to identify PAS for all genes will need to be developed. While 
trivial for many genes, this is challenging for others as some use multiple polyadenylation sites 
and often the PAS sequence does not conform to the consensus, as demonstrated for a number 
of the genes that we reviewed. Third, to the extent that exome analysis continues to outpace 
genome analysis, it will be necessary to target these sequences in exome capture reagents. 
Fourth, testing laboratories will need to direct their attention to detecting and interpreting such 
variants. Finally, criteria for pathogenicity of non-coding variants will need to be updated. We 
believe that the accomplishment of these improvements in variant detection, interrogation, 
and interpretation will allow the findings based on the three variants reported here as a cause 
of a rare disorder to yield benefits for the diagnosis of patients with many other genetic 
disorders and contribute to the overall improvement in clinical genomic sequencing diagnostic 
yield. 
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Figure 1. Pedigrees for families 1 to 3. Clinically affected individuals are depicted by filled 
symbols, black symbols depict individuals with eye findings, grey symbols depict individuals 
without eye findings, genotypes of tested individuals are noted. 
Figure 2. Reverse transcription and quantitative PCR analysis of NAA10 expression in mRNA, 
data were normalized to ACTB mRNA levels. Panel A, relative NAA10 expression in whole blood 
from affected individuals (family 1, individuals III-2, III-5 and IV-3), carrier females (family 1, 
individuals II-2, II-6 and III-15) and male and female control individuals (C1-C4). All values are 
shown relative to control C1. Panel B, NAA10 expression levels in lymphoblasts from affected 
male IV-6 shown relative to the expression level in unaffected male V-9, family 2. 
Figure 3. RNA-seq data comparing reads from four affected individuals, two carrier females and 
three control individuals, one female and two males, for NAA10. The variant positions in the 
NAA10 polyadenylation signal are marked by a filled red arrow. Transcription in affected 
individuals (family 1, individuals III-2, III-5 and IV-3 and family 2, individual IV-6) and carrier 
females (family 1, individuals II-2 and III-15) continues past the normal polyadenylation 
cleavage site and uses a cryptic signal approximately 600 bp downstream at an alternate 
polyadenylation cleavage site depicted by an open red arrow. NAA10 gene models are from 
GENCODE Version 19 as included in the UCSC genome browser (GRCh37/hg19).
Figure 4. Comparison of the effects of AAUAAA mutations on cleavage and poly (A) addition. 
Variants identified in this study are noted with an asterisk. Figure is reproduced from Sheets et 
al. 1990 with permission from Oxford University Press.[34]
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Table 1. NAA10 polyadenylation signal variants identified in microphthalmia/anophthalmia and review of polyadenylation signal 
alterations as reported in HGMD.
Gene WTa Variant HGMD ID HGMD 
pathogenicity
ClinVar Descriptor GRCh37 Position & 
Variation
ClinVar 
variation ID
ClinVar Assertion PMID
NAA10 AATAGA ChrX:153195397T>C
NAA10 GATAAA ChrX:153195401T>C
NAA10 AGTAAA ChrX:153195400T>C
BMP1 AGTAAA AGCAAA CR150372 DM NM_001199.3(BMP1):c.*241T>C Chr8:22058957T>C 190231 Pathogenic 25214535
F9 AATGAA CR005437 DM 11013449
FOXP3 AATGAA CR014834 DM 11685453
FOXP3 AATAAG CR097218 DM 19471859
GLA ATTAAAga ATTAGA CD031841 DM 12796853
HBA2 AATAAG CR830007 DM 6646217
HBA2 AATGAA CR920785 DM NM_000517.4(HBA2):c.*92A>G Chr16:223691A>G 15647 Pathogenic/Likely 
Pathogenic
1581238
HBA2 AATAAC CR106042 DM 19912309
HBA2 AATAAAgt AATAGT CD941949 DM 7803252
HBB AAAAAA CR045224 DM 15481893
HBB AAGAAA CR014260 DM 11300343
HBB AATATA CR057232 DM 15820953
HBB AACAAA CR850010 DM NM_000518.4(HBB):c.*110T>C Chr11:5246718A>G 36332 Pathogenic 4018033
HBB AATAAG CR880076 DM NM_000518.4(HBB):c.*113A>G Chr11:5246715T>C 15473 Pathogenic 3048433
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
HBB AATGAA CR900265 DM NM_000518.4(HBB):c.*111A>G Chr11:5246717T>C 15488 Pathogenic 2375910
HBB AATAGA CR900266 DM NM_000518.4(HBB):c.*112A>G Chr11:5246716T>C 15476 Pathogenic 2375910
HBB CATAAA CR016252 DM 11722440
HBB GATAAA CR127145 DM 22862814
HBD AATTAA CR109506 DM 20854114
IGF1 AATATA AAAATA CR033689 DM 14684690
IL2RG AATAAG CR0910465 DM 19841577
INS AATAAG CR101141 DM NM_000207.2(INS):c.*59A>G Chr11:2181023T>C 65581 Pathogenic 20133622
ITGA2B AACAAA CR153724 DM 25728920
ABCG2 AAATGA AAGTGA CR1718077 DP 28930109
ARSA AATAAC AGTAAC CR890137 DP NM_000487.5(ARSA):c.*96A>G Chr22:51063477T>C 3049 Conflicting 2574462
HES7 AAAATC AAGATC CR1510755 DM? 25928698
NAT1 AAAAAA CR1111021 FP 7585580
PEX6 AATAAAcaca AACACA CD1716837 FP 29220678
PTGFR AATGAA CR156013 DFP 25977569
SLC6A4 ATTAAC AGTAAC CR102248 DFP 19969287
TP53 AATACA CR118782 DFP 21946351
aWild type is AATAAA unless otherwise specified. Underlined nucleotides are deleted and the nucleotides given in lower case are shifted into the variant hexamer. Thymidine is specified instead of 
uracil, referencing the genomic sequence, rather than the mRNA.
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
+m/m/
m/m/m/ +/
m/
m/+ +/ m/+ +/ +/ +/
m/+
m/+
+/
m/+
I
II
III
IV
1 2 3 4
1 2 3 4
1 2 3 4 5 6 7 8
5 6 7 8
9 10 11 12
9 10 11 12
13 14 15 16 17 18
13 14 15 16
1 2 3
A
B C
c.*43A>G 
c.*39A>G c.*40A>G 
m/+
1
1 2
2
m/
I
II
1
1 2 3
2 3 4
1 2 3 5 6
1 2 3 4 5 6 7 8 9 10 11
I
II
III
IV
V
1 2 3
m/
4
m/+m/+
m/+ +/ +/
m/
Figure 1
m/+m/+
+/+
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
C1♀   C2♀     C3♂   C4♂    II-2     II-6     III-15   III-2    III-5   IV-3 V-9♂   IV-6
R
el
at
iv
e 
Q
ua
nt
ita
tio
n
R
el
at
iv
e 
Q
ua
nt
ita
tio
n
Controls
Carrier females
Affected males
0.0
0.2
0.4
0.6
0.8
1.0
A B
Figure 21
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
NAA10
Transcripts
NAA10
NAA10
NAA10
2 kbhg19
153,196,000153,197,000153,198,000153,199,000ChrX:153,200,000
Family 1 individual III-2, affected male
Family 1 individual III-5, affected male
Family 1 individual IV-3, affected male
Family 1 individual II-2, carrier female
Family 1 individual III-15, carrier female
Family 2 individual IV-6, affected male
Family 2 individual V-9, unaffected  male
Control, unaffected male
Control, unaffected female
A
B
C
D
E
F
G
H
I
Figure 31
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
100 
80 
60 
40 
20 
0 
AA
UA
AA
 
AU
UA
AA
AG
UA
AA
 
CA
UA
AA
 
GA
UA
AA
 
AC
UA
AA
 
AA
UA
GA
 
Polyadenylation
(% of AAUAAA)
Cleavage
(% of AAUAAA)
***
Figure 41
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
